3 news items
FibroGen Reports First Quarter 2024 Financial Results
FGEN
6 May 24
Pipeline Initial data from Phase 1 investigator-initiated combination study of FG-3246 with enzalutamide in metastatic castration
FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meeting
FGEN
24 Apr 24
anti-tumor activity in both preclinical and clinical studies. FG-3246 is currently in an ongoing investigator-initiated Phase 1b/2 study being conducted
FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer
FGEN
2 Apr 24
Investigator of the study. "The observed median radiographic progression free survival of 8.7 months in patients treated with a starting FG-3246 dose
- Prev
- 1
- Next